EUVIMEDEuropean Health Evidence
Uhr 7/7Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

18F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer

Ismaheel O. Lawal, Lara R. Harik, Akshay S. Bedmutha, Sagar A. Patel, Ashesh B. Jani, David M. Schuster

Clinical Nuclear Medicine · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

A 67-year-old man with rising PSA and palpable prostate lesion underwent prostate MRI, which showed a large PI-RADS 5 lesion confirmed on biopsy as Gleason score 9 (4+5), grade group 5, prostate cancer. 18 F-DCFPyL PET/CT scan for initial stage showed no significant PSMA avidity in the prostate lesion. 18 F-fluciclovine was obtained for off-label disease staging and management guidance. The high Gleason score prostate lesion showed intense 18 F-fluciclovine avidity. High expression of amino acid transporters and low PSMA expression was confirmed by immunohistochemistry. This case showcases a non-PSMA-avid primary prostate cancer with intense 18 F-fluciclovine, demonstrating the potential of 18 F-fluciclovine PET/CT as an off-label alternative in the uncommon primary prostate cancer without significant PSMA expression.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Ismaheel O. Lawal, Lara R. Harik, Akshay S. Bedmutha, Sagar A. Patel, Ashesh B. Jani, David M. Schuster
Quelle
Clinical Nuclear Medicine
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
0363-9762, 1536-0229
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Ismaheel O. Lawal, Lara R. Harik, Akshay S. Bedmutha, Sagar A. Patel, Ashesh B. Jani, David M. Schuster (2026). 18F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer. Clinical Nuclear Medicine. https://doi.org/10.1097/rlu.0000000000006659
RIS BibTeX CSL-JSON